It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.

Research output: Contribution to journalArticle

Original languageUnknown
JournalRecent Patents On Anti-Infective Drug Discovery
Volume6
Publication statusPublished - 1 Jan 2011

Cite this